Drug makers in Uruguay will have to include braille labels

Uruguay’s Senate this week ruled in favor of drug labels being adapted for people with visual disabilities. After being presented to the court two years ago, the bill was approved without deliberation and now awaits ratification by the executive authority.

Laboratories will have a two-year period to adapt their products to include in their box, packaging, or wrapping a reading system for the visually impaired, detailing as a minimum the medicine’s active ingredient, presentation, and brand name. This information will be provided using braille system or a QR code that users can scan with a device.

It is estimated that 10% of Uruguay’s population have a visual disability, of which 60,000 have a serious disability and 5,000 are blind.


Recent news
Nelson Mussolini, head of Brazil’s Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) and member of the National Health Council, this week voiced his position against the government’s control of drug prices and the high tax rates.
The Center for State Control of Drugs and Medical Devices (CECMED) last week cleared Catalonia (Spain)-based Laboratorio Estedi’s Ursobilane (ursodeoxycholic acid) for the Cuba market, GBI analysis reveals.
According to GBI analysis, Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) this week granted marketing authorization to Japan-based Otsuka Pharmaceutical’s drug-resistant tuberculosis (TB) treatment Deltyba (delamanid).
China-based Sino Biopharmaceutical Ltd (HKEX.01177) announced the signing of a joint venture (JV) agreement between its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, and Akeso Biopharma Inc​.
A team of Chinese scientists led by Professor Ma Xiong, from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Renji Hospital)'s gastroenterology department, has uncovered the characteristics of intestinal flora in patients with autoimmune hepatitis (AIH), according to the hospital.
  • 1560834410023
  • China
  • R&D
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
Colombia’s National Food and Drug Surveillance Institute (INVIMA) this week issued marketing approval to Johnson & Johnson (J&J) subsidiary Janssen’s oral cancer drug Erleada (apalutamide).